US Patent

US10406199 — Lisinopril formulations

Method of Use · Assigned to Silvergate Pharmaceuticals Inc · Expires 2035-11-06 · 9y remaining

Vulnerability score 45/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects stable lisinopril oral liquid formulations and methods of using them to treat hypertension, heart failure, and acute myocardial infarction.

USPTO Abstract

Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.

Drugs covered by this patent

Zestril (lisinopril) · Generic (originally Merck/AstraZeneca)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1864`	—	Zestril

Patent Metadata

Patent number: US10406199
Jurisdiction: US
Classification: Method of Use
Expires: 2035-11-06
Drug substance claim: No
Drug product claim: No
Assignee: Silvergate Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.